Background: MicroRNAs (miRNAs) are endogenous non-coding RNAs, 19-25 nucleotides in length, involved in post-transcriptional regulation of gene expression in a considerable majority of mRNAs. Different aspects of cellular activities like cell growth, proliferation, and differentiation are regulated by miRNAs through their regulatory effects on particular RNA species. In many tumors, up-or down-regulation of different miRNAs has been reported. In acute myeloid leukemia, up-regulation of miR-92a has been reported in human in-vitro studies.
INTRODUCTION
MicroRNAs (miRNAs), 19-25 nucleotide length ribonucleic acids, [1] play a crucial role in the regulation of gene expression. Initially discovered
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Inhibition of oncogenic miRNAs (called oncomiRs) is of potential application for the treatment of cancers. Several methods have been tested for inhibition of miRNAs. [8, 10, [14] [15] [16] Locked Nucleic Acid (LNA) is a new lineage of a modified oligonucleotide that has a 2'-O 4'-C Methylene bridge in its structure, leading to stability in high temperature and resistance to enzymatic degradation. [17] The efficacy and safety of LNA-anti-miRs for inhibition of miRNAs has been shown in several studies, suggesting that they are suitable candidates for therapeutic applications. [17] [18] [19] [20] Acute myeloid leukemia (AML) is a disorder of hematopoietic stem cells, accompanied with obstruction in hematopoietic cell differentiation and increased clonal neoplastic proliferation. Untreated, this malignancy leads to death within a few weeks to several months. [21, 22] Despite extensive studies, the biological and pathophysiological aspects of AML are not yet clearly known. [23, 24] miRNAs, as influential players in cell function, can potentially shed light on the pathogenesis of this disorder. In recent times, it has been shown that there is an increased expression of miR-92a in AML. [25] [26] [27] This miRNA has also been shown to negatively regulate p63, leading to increased proliferation of myeloid cells. [28] miR-92a is a member of the miR-17-92 cluster located on chromosome 13q31.3. This cluster is suggested to function as oncomiR in some other malignancies. [29] Based on these evidences, we have proposed that inhibition of miR-92a is of therapeutic effect in AML. According to the American-French-British (FAB) classification, AML is divided into eight subtypes, M0-M7. [22] In this study, HL-60 cells have been used as an in vitro model of AML-M3, also known as acute promyelocytic leukemia (APL), to investigate the effect of LNA-anti-miR-92a transfection on cell viability and apoptosis/necrosis. The results of this study may pave the way for new therapies for AML.
MATERIALS AND METHODS

Cell culture
The HL-60 cell line (Human Acute Promyelocytic Leukemia: APL) was purchased from the National Cell Bank of Iran (Pasteur Institute, Iran). The cell culture was maintained in Roswell Park Memorial Institute (RPMI) 1640 (Gibco, UK) supplemented with fetal calf serum (FCS; Gibco, UK) 15% v/v, 100 U/ml of penicillin and 100 μg/ml of streptomycin (Sigma-Aldrich, USA) in an air-saturated and humid atmosphere, consisting of 5% CO2, in 25-cm 2 culture flasks (Nunc, Denmark), at 37°C. The cells were passaged twice weekly to maintain an exponential growth phase.
Cell transfection
T h e n u c l e o t i d e s e q u e n c e s o f m i R -9 2 a w e r e o b t a i n e d f r o m w w w . m i r b a s e . o r g a s UAUUGCACUUGUCCCGGCCUGU (accession number MIMAT0000092). miRCURY LNA microRNA Inhibitor™ for hsa-miR-92a and microRNA inhibitor negative control (scrambled) oligonucleotides were purchased from Exiqon, Denmark. Both oligonucleotides were labeled at the 5' end with fluorescent dye, 6-FAM.
HL-60 cell transfection was performed by using the X-treme GENE siRNA Transfection Reagent™ (Roche, Germany) according to the manufacturer instructions. Briefly, 5 × 10 5 cells in the exponential growth phase were cultured in six-well culture plates (Nunc, Denmark) containing 1.8 ml RPMI 1640 per well without antibiotic or FCS. The fifty picomol miRCURY LNA microRNA Inhibitor™ was mixed with 5 μL X-tremeGENE siRNA Transfection Reagent™ in 200 μl Opti-MEM I Medium™ (Gibco, UK) and incubated for 15 minutes at room temperature. The complex was then added to the cells and swirled cautiously to ensure even distribution over the entire plate surface. After eight hours of incubation, the FCS and antibiotics were added and the cells were incubated for the 24, 48, and 72 hours. Untreated cells and cells transfected with scrambled-LNA were cultured parallel to the LNA-anti-miR transfected cells. Evaluation of the transfection was detected by flow cytometry and fluorescent microscopy. LNA was conjugated with 6-FAM™ Fluoresceine (6-carboxyfluorescein) and HL-60 cells, which transfected with the LNA, and was seen by a fluorescence microscope and analyzed by a FACSCalibur flow cytometer (BD, USA).
Reverse transcriptase microRNA real time polymerase chain reaction
Reverse transcriptase (RT) microRNA real time PCR was performed to determine the efficiency of miR-92a inhibition by LNA-anti-miR. Briefly, the total cellular RNA was extracted 24, 48, and 72 hours post transfection, with a miRCURY RNA Isolation Kit™ (Exiqon, Denmark) and cDNA was synthesized with a Universal cDNA Synthesis Kit™ (Exiqon, Denmark). Real time PCR was performed by using the SYBR ® Green master mix Kit™ (Exiqon, Denmark) and specific miR-92a primers were obtained from Exiqon (product No: 1204258; Exiqon, Denmark). The ABI Step One Plus (ABI, USA) instrument was used for real time PCR experiments and the ΔΔCt method was used for data calculation.
Apoptosis and necrosis assay
The Annexin-V-FLUOS Staining Kit (Roche, Germany) was used for detection of apoptosis and necrosis in HL-60 cells. Annexin-V was used to detect the phosphatidylserine on apoptotic cells. To discriminate necrotic cells Propidium Iodide (PI) staining was employed. The procedure was performed 24, 48, and 72 hours after transfection, according to the manufacturer's instruction (untreated cells were used for controls), and the cells were assessed by the FACSCalibur flow cytometer (BD, USA) with 488 nm excitation, 515 nm band pass filter for fluorescein-conjugated Annexin-V detection, and a filter > 600 nm for PI detection.
Statistical analysis
All the experiments were carried out in triplicate. The results were calculated by using the IBM SPSS (version 20) software. The Kruskal-Wallis and Mann-Whitney tests were used to assess the differences between the groups. Data were presented as Mean ± SD. Statistical significance was defined as P < 0.05.
RESULTS
miRCURY LNA microRNA inhibitor™ strongly inhibits miR-92a
For inhibition of miR-92a, the miRCURY LNA microRNA Inhibitor™ was transfected to HL-60 cells with the X-tremeGENE siRNA Transfection Reagent™. On the basis of the initial optimization experiments, transfection was performed with 50 pM of LNA-anti-miR and 5 μl of the transfection reagent. As the transfected oligonucleotides were fluorochrome-conjugated, transfection efficiencies was assessed by fluorescence microscopy and flow cytometry. At the optimized level, transfection efficiency was about 90% [ Figure 1 ].
Expression of miR-92a was evaluated by reverse transcriptase microRNA real time PCR in HL-60 cells transfected with the miRCURY LNA microRNA Inhibitor™ (LNA-anti-miR group), transfected with the microRNA inhibitor scrambled oligonucleotides (scrambled LNA group), and untreated HL-60 cells (untreated groups), at 24, 48, and 72 hours after transfection. Although, miR-92a expression was a little bit lower in the scrambled LNA-transfected cells compared to the untreated cells, the differences were not biologically significant and the miR-92a level was in the same order in these two groups. However, in all three time points, the expression of miR-92a was considerably lower in the LNA-anti-miR group compared to the control group (P < 0.025). The expression of miR-92a was at the lowest level 24 hours after transfection and gradually increased in the next two time points [ Figure 2 ].
Inhibition of miR-92a increased apoptosis and necrosis in HL-60 cells
To evaluate the effect of miR-92a inhibition on apoptosis and necrosis, the cells were stained with Annexine-V and PI 24, 48 and 72 hours after transfection. The apoptotic cells were almost undetectable in the untreated cells. However, the ratio of these cells minimally increased 48 and 72 hours after scrambled LNA transfection compared to the untreated cells. MiR-92a inhibition was associated with a dramatic increase in apoptosis, as the ratio of apoptic cells in the LNA-anti-miR group was higher than that in the other groups, at the three time points (P < 0.028 for all time points; Figure 3 ).
In line with the data of the apoptosis assay, necrosis in the untreated cells was undetectable, but the ratio of the necrotic cells minimally increased 48 and 72 hours after scrambled LNA transfection compared to the untreated cells. The ratio of necrotic cells in the LNA-anti-miR group was higher than that in the other groups, at the three time points, which showed that inhibition of miR-92a was associated with increment of necrosis in the HL-60 cells (P < 0.045 for all time points; Figure 4 ).
DISCUSSION
In this study, we have used LNA-anti-miR to inhibit miR-92a in an APL (AML-M3) cell line. Real time PCR data confirmed that this miRNA was almost entirely down-regulated after LNA-anti-miR transfection. The apoptosis/necrosis assay, showed that LNA-anti-miR-92a transfection significantly increased apoptosis and necrosis. In these assays, the effect of LNA-anti-miR-92a transfection on cell viability was much higher than in the basal transfection reagent toxicity observed with scrambled oligonucleotide transfection.
In addition, we acknowledge that our Annexin-V/PI staining method cannot discriminate between late apoptosis and necrosis. However, our data indicates that inhibition of miR-92a can increase the apoptosis and necrosis of APL cells and this is at least partially due to the induction of apoptosis.
MiR-92a seems to be involved in cell cycle regulation and cell signaling, therefore, it has a role in cell development and proliferation. [27, 30] Overexpression of miR-92a may act as an oncogene or down-regulated tumor suppressor genes, or may affect the genes that control apoptosis and cell differentiation. [31] miR-92a has a function in leukemia, from AML to ALL, in hepatocellular carcinoma, and several other cancers. [25, 32] There is evidence which suggests that miR-92a targets an estrogen receptor (ERβ1) mRNA and suppresses its expression in breast cancer. [33] In AML, the miR-92a increases. In addition, it is reported that this miRNA negatively regulates p63 in CD32 cells, leading to increased proliferation of murine myeloid cells. [28] Acute myeloid leukemia is associated with a high rate of morbidity and mortality, [21] and in spite of recent progresses, the current treatment options for this disorder are suboptimal. There are a number of studies on oncomiRs as an approach to cancer treatment, and attempts have been made to treat cancer by using miRNA inhibitors. [8] [9] [10] 15] Many studies are in the early phase and some of them are in other phases. [15] LNA is one of the Anti-miRs that is used for inhibiting oncomiRs. [17] In this study, specified inhibition of miR-92a by using LNA-anti-miR has prevented proliferation of APL cells and it seems that it is an oncomiR in APL. With regard to the treatment of cancer, destruction of cells that have uncontrolled proliferation is the aim, perhaps by using LNA-anti-miR for inhibiting miR-92a, which can treat APL. This seems to be the method for AML treatment. Chemotherapy is a routine approach for AML treatment. [21, 23, 24] In many cases chemotherapy does not affect AML and cannot reduce the proliferative cells. Some efforts have been initiated for treating cancer by using Anti-oncomiRs (oncomiR-inhibitors) with other drugs, for example, chemotherapy agents. [22, 24] It is suggested that Anti-miR-92a can be used, accompanied by other anti-cancer drugs, for treatment of APL. All-trans retinoic acid (ATRA) is a routine drug that is used for treating APL, but it is not always successful. [22] This study suggests that
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Anti mir-92a can be used with or without ATRA for treating APL, which is resistant to treatment.
CONCLUSION
Our data suggests that inhibition of miR-92a with LNA-anti-miR can be potentially used for the treatment of APL. It can be used alone or in combination with the current therapies, to reduce the existing limitations in the treatment of this disorder. Further in vivo studies are definitely required to assess the feasibility of this strategy. However, efficient in vivo delivery of anti-miR oligonucleotides remains an obstacle to be tackled before we can move to clinical trials.
